Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 58Sarcoma 39Neoplasm Metastasis 22Neoplasms 20Ovarian Neoplasms 17Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Recurrence 7Leiomyosarcoma 7Kidney Neoplasms 7Melanoma 6Liposarcoma 6Hemangiosarcoma 6Glioblastoma 6Fallopian Tube Neoplasms 6Thyroid Neoplasms 5Prostatic Neoplasms 5Neurofibrosarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Dermatofibrosarcoma 4Clear-cell metastatic renal cell carcinoma 4Chondrosarcoma, Extraskeletal Myxoid 4Uterine Cervical Neoplasms 3Solid Tumors 3Small Cell Lung Carcinoma 3

Interventions

Temozolomide 2Omeprazole 2Lansoprazole 2Esomeprazole 2Capecitabine 2veliparib 1pazopanib 1cixutumumab 1YF 476 1Streptozocin 1Salts 1Pantoprazole 1Octreotide 1Interferons 1Fluorouracil 1Everolimus 1Doxorubicin 1Dexlansoprazole 1Clopidogrel 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Zollinger-Ellison Syndrome × pazopanib × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡